Regen BioPharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RGBPP research report →
Companywww.regenbiopharmainc.com
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease.
- CEO
- David Raymond Koos
- IPO
- 2016
- Employees
- 1
- HQ
- La Mesa, CA, US
Price Chart
Valuation
- Market Cap
- $186.41K
- P/E
- -0.10
- P/S
- 0.05
- P/B
- -0.01
- EV/EBITDA
- -0.75
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 75.03%
- Op Margin
- -367.41%
- Net Margin
- -302.54%
- ROE
- 11.91%
- ROIC
- 19.79%
Growth & Income
- Revenue
- $236.56K · 0.00%
- Net Income
- $-1,274,502 · -90.72%
- EPS
- $-0.03 · 76.19%
- Op Income
- $-338,540
- FCF YoY
- 48.96%
Performance & Tape
- 52W High
- $0.10
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.02
- Beta
- 1.93
- Avg Volume
- 320.63K
Get TickerSpark's AI analysis on RGBPP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our RGBPP Coverage
We haven't published any research on RGBPP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RGBPP Report →